

www.imdcal.com

21st September, 2023

To, To, **Department of Corporate Services** The Manager, Listing Department, BSE Ltd. Phiroze Jeejeebhoy Towers, National Stock Exchange of India Ltd. Dalal Street, "Exchange Plaza", C-1, Block G, Bandra-Kurla Complex, Mumbai – 400 001. Bandra (E), Mumbai – 400 051. Ref.: Scrip Code No.: 540701 (Equity) Ref.: (i) Symbol – DCAL : 974556 (Debt) (ii) Series – EQ

SUB.: DISCLOSURE PURSUANT TO REGULATIONS 30 AND 51 OF SEBI (LODR) REGULATIONS, 2015: SUCCESSFUL COMPLETION OF EDQM INSPECTION OF COMPANY'S BAVLA SITE

Dear Sir,

As informed earlier, there was a joint inspection carried out during the quarter ending March, 2020 by the Swissmedic and European Directorate for the Quality of Medicines & HealthCare (EDQM), due to which there were certain audit observations issued deficient to EU GMP Part II and other relevant Annexes for the Company's Bavla site.

Further, pursuant to implementation of the Corrective Action Plan submitted to the EDQM on 21st August, 2020, the Company had informed the EDQM on 18th October, 2022 regarding its readiness for a re-inspection of its Bavla site with an objective of getting a clearance for this site by the EDQM and in this regard the re-inspection by the EDQM of the Bavla site was scheduled from 18th September, 2023 to 20th September, 2023.

In this regard, we would like to inform that the Company's Bavla site was successfully jointly inspected by the EDQM and Italian Medicines Agency (AIFA) during the above period though the final report is awaited.



www.imdcal.com

We will keep the stock exchanges further informed if there is any material information relating to the above in the future.

This is for your kind information and record.

Thanking you.

Yours faithfully, For, Dishman Carbogen Amcis Limited

Shrima Dave Company Secretary